A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment. P

Trial Details

NCT ID
NCT06242470
Phase
PHASE1
Sponsor
MacroGenics
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • MGC026 Dose Escalation
  • MGC026 Dose for Expansion
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Lake Success, New York, United States|40.77066,-73.71763
  • Portland, Oregon, United States|45.52345,-122.67621
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Adults ≥ 18 years old, able to provide informed consent
  • Adequate performance and laboratory parameters
  • Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specime…
  • Unresectable, locally advanced or metastatic solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →